Tesamorelin Dosage and the Growth Hormone Signal Behind It

Tesamorelin dosage questions are easier to answer once you know which receptor the molecule presses. It is a copy of the brain hormone that tells the pituitary gland to release growth hormone, and the body answers with feedback of its own. This guide follows that signal, then sets out what the approved label says and why claims beyond the label have no established dose behind them.

The Receptor That Tesamorelin Presses

Growth hormone starts with a message from the hypothalamus, a small control center at the base of the brain. That message is a peptide called growth hormone releasing hormone, or GHRH. It travels a short distance to the pituitary gland and fits a receptor on cells called somatotrophs. The Egrifta label states that tesamorelin binds and stimulates the human receptor with similar potency to the natural hormone. Once the receptor fires, the cell makes and releases growth hormone. The first stop on the Signal line explains why a key can only fit one kind of lock, and this is a clean example: one hormone, one receptor, one cell type.

Growth hormone does not leave the pituitary in a steady stream. It comes in pulses, and the label describes the natural hormone as stimulating the synthesis and pulsatile release of growth hormone. A second hormone, somatostatin, acts as a brake. In a 1985 study of healthy men given a continuous infusion of the natural releasing hormone, pulses persisted, and the authors proposed that each pulse reflects releasing hormone coupled with a withdrawal of somatostatin. Growth hormone then acts on many tissues, partly through IGF-1 made in the liver. The label notes that tesamorelin raises IGF-1 and IGFBP-3 without clinically significant changes in TSH, LH, ACTH or prolactin.

What the Egrifta Label Says About Dosing

Tesamorelin is approved, which makes it unusual among the compounds on this blog. The label for Egrifta WR, revised in March 2025, covers one use: reducing excess abdominal fat in adults with HIV who have lipodystrophy. For that use it states one fixed amount, 1.28 mg once daily under the skin of the abdomen, with injection sites rotated around the abdomen and never into scar tissue, bruises or the navel. That is the tesamorelin dosage per day on the label, and it applies only to that product and that indication. The older Egrifta SV formulation has a different amount and the label says the two are not substitutable, so even approved tesamorelin dosing cannot be swapped between vials.

People also ask about tesamorelin dosage for men. The label gives no separate figure by sex, and it reflects trials in which most participants were men, between 84 and 90 percent in the pooled groups the label describes. That is a fact about who was studied, not a men only dose. Anyone searching for a tesamorelin protocol in a forum is looking at a stack of personal reports. A prescribed product follows the label, and a prescriber adjusts it using IGF-1 results and the safety warnings. The same applies to any tesamorelin peptide dosage chart found online: the figures are not the label figures, and nobody checks them against blood tests or scans.

Tesamorelin Half Life and the IGF 1 Feedback Loop

The label gives a mean elimination half-life of 11 minutes for Egrifta WR in healthy subjects after a single injection. Such a short tesamorelin half life seems odd for a once daily drug, but the half-life of the molecule is not the half-life of the signal. Growth hormone released after the injection lasts longer, and IGF-1 lasts longer still, because the liver keeps making it and carrier proteins hold it in the blood. The effect on the pituitary is a short, sharp push, followed by a slower body wide response. That is also why researchers cannot read a dose straight from the half-life of the drug.

IGF-1 then closes the loop. In normal physiology a rising IGF-1 level tells the brain and pituitary to reduce the signal, which keeps the axis in balance. A drug that pushes the receptor from outside works on top of this loop, and the label shows the result. Among patients treated for 26 weeks, 47 percent had IGF-1 above 2 standard deviation scores and 36 percent above 3, and the label tells prescribers to monitor IGF-1 and consider stopping if it stays high. The effects of long periods of raised IGF-1 are listed as unknown. That monitoring is a clinic tool, and it does not exist for someone injecting a vial bought online.

Weight Loss Bodybuilding and Fat Loss Claims

Searches for tesamorelin dosage for weight loss, tesamorelin dosage for bodybuilding and tesamorelin dosage for fat loss all ask about uses the label does not cover. The label says plainly that Egrifta is not indicated for weight loss management and that its effect on weight is neutral. It targets visceral abdominal fat in one defined group of patients, measured by scans. No established dose exists for healthy people who want to lose weight or build muscle, because the approved trials did not test those uses. Fixed figures that appear in blogs and videos come from vendors and personal anecdotes, and they cannot be checked.

There are also reasons to be careful with the idea of simply pressing the receptor harder or more often. The label warns about raised IGF-1, fluid retention, glucose intolerance and the unknown long term effect on heart health, and it lists injection site reactions as common. Other growth hormone releasing products, such as the combination discussed in the CJC 1295 stops, are unapproved, and their human data are thin. Readers who want to understand the axis should start with the pulses and the feedback described above. A person who wants treatment for a medical reason should talk to a clinician, who can prescribe an approved product and monitor it.

Conclusion

The approved tesamorelin dosage is one fixed label amount for one group of patients with HIV lipodystrophy, with IGF-1 checks and an 11 minute half-life that hides a longer hormone response. For weight loss, bodybuilding or fat loss there is no established dose, and the label says the drug is not for weight loss. Understanding the pulses and feedback explains why.